Kayoko Goya
Japan
Research Article
Sitagliptin Significantly Decreases the Ratio of Glycated Albumin to HbA1c in Patients with Type 2 Diabetes Mellitus
Author(s): Shogo Kurebayashi, Takashi Motomura, Kayoko Goya, Makoto Nakao, Kunihiko Hashimoto, Yasuhiko Morimoto, Tetsuhiro Kitamura, Atsunori Fukuhara, Bunzo Sato, Soji Kasayama, Iichiro Shimomura, Masafumi Koga and Michio OtsukiShogo Kurebayashi, Takashi Motomura, Kayoko Goya, Makoto Nakao, Kunihiko Hashimoto, Yasuhiko Morimoto, Tetsuhiro Kitamura, Atsunori Fukuhara, Bunzo Sato, Soji Kasayama, Iichiro Shimomura, Masafumi Koga and Michio Otsuki
Background: Since glycated albumin (GA) is a glycemic control marker which reflects more postprandial plasma glucose (PPPG) and/or glycemic excursions than HbA1c, the GA/HbA1c ratio is a useful indicator for PPPG and/or glycemic excursions. In this study, we investigated the clinical significance of the GA/HbA1c ratio by administration of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes mellitus.
Methods: Sitagliptin (50 mg/day) was administered for 24 weeks to 69 patients with type 2 diabetes mellitus with stable glycemic control.
Results: With sitagliptin administration, both HbA1c and GA significantly decreased from baseline to the periods of week 4 and week 24. The GA/HbA1c ratio also significantly decreased (baseline 2.72 ± 0.42 vs. 24 weeks 2.60 ± 0.38, P<0.0001). The .. View More»
